Dose Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

To apply for authorization. there was an add layer as you mentioned, which is that they were encouraged to apply for authorization which gives a sense that the regulators have seen something encouraging in the date. a the only thing we heard until today, late last night, was that the two doses in children between amings of 2 and 5 did not seem to be generating a strong immune response. so i don't know if the regulators are saying we're very encouraged that a third dose will be enough to generate that immune response but we don't want to wait for the third dose data. we think it is time get mov...

Two-dose vaccine ages -- for the higher range, 2 to 5 or 2 to 4, didn't show much antibody production or didn't show much increase in boosted immunity. totally safe. they found it was totally safe which is why they're willing to give an authorization right now, but what's interesting to me is why move forward until they've seen data that it's protective? >> yeah. that is the big question. i think for up until just recently i think the thinking was let's wait to see what that third dose data sort of shows here. i think the belief is that, look, we have this other data from older children. we ha...

Much of an immune response, it is safe so we should get started on getting shots into kids arms. one quote from the "washington post" on this. we know two doses isn't enough and we get that, says one of the people familiar with the situation. the idea is, let's go ahead and start the review of two doses. if the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don't do anything until the third dose data comes in. what do you think of that? >> that assume that the third dose works, it's safe and effective, which is an assumption i think n...

Pfizer to submit their two dose data to them for authorization, they said in part this afternoon that the fda felt it was their responsibility as a public health agency to act with urgency and have all available options including they provide us with initial data on two doses from the on going study, their goal was to understand if two dose was provide sufficient protection. remember, we had press release information already in december from pfizer that said, you know, there two dose regimen in this age-group did not trigger a comparable immune response as what was seen in 16 to 25-year-olds. ...

Needed. the surge in omicron cases also brought on a flood of new data that led them to their decision today. >> makes sense for us to wait until we have the data from evaluation of a third dose before taking action. >> pfizer and its research partner bion tech issued this statement given that the study is advancing at rapid pace, the companies will wait for the three dose data as pfizer and bion tech continue to believe it may provide a higher level of protection in this age group. the companies expect to have the data in early april. the hold up is over questions about effectiveness rather t...